ProCatid Medical

ProCatid Medical Overview

ProCatid Medical is the developer of WIRION, a distal embolic protection system composed of an independent filter unit that can be delivered, locked, and deployed on any commercially marketed guide wires, according to physician preference. The unit can be placed anywhere on the wire using minimally invasive interventional procedures. The WIRION system allows the physician to use any 0.014-inch guide wire of choice throughout the entire procedure, cross challenging anatomies, and lock the filter on the same guide wire anywhere along the wire. The one-size system covers vessels ranging between 3.5 mm and 6.0 mm in diameter. Its uniform 120-micron pore filter provides continuous blood flow while maintaining embolic capture efficiency. It is currently designed for use in stenting procedures, including carotid, renal, lower limb, coronary, and SVG angioplasty. The system is CE marked and FDA cleared. ProCatid Medical is a subsidiary of Allium Medical, which develops minimally invasive solutions for treating chronic progressive diseases. In August 2019, the ProCatid Medical entered into an asset purchase agreement with Cardiovascular Systems Inc for the acquisition of certain assets and rights in relation to the WIRION system.

Latest News

Aug 6, 2019 · www.calcalistech.com

growth-positive

Medtech Company CSI Acquires Assets of Israeli Company Gardia for $17 Million

Cardiovascular Systems Inc. (CSI) has acquired some assets of Israel-based Gardia Medical for $17 million plus royalties, as announced by Gardias parent company Alium Medical Ltd. The assets include Gardias WIRION system, which helps reduce complications during minimally invasive interventional procedures. CSI paid $7 million during the signing of the agreement, $5.6 million of it in cash and the rest in stock, and another $10 million will be paid when the manufacturing business changes hands.

Acquisition

Oct 23, 2018 · www.calcalistech.com

growth-positive

Boston Scientific Signed a Distribution Deal with Israeli Allium Medical

Allium and Boston Scientific have signed an agreement giving Boston Scientific exclusive distribution rights in the U.S. for an Allium stenting assistance system. Allium estimates that the agreement could bring in NIS 70 million ($19 million) if Boston Scientific expands the agreement to global distribution. Boston Scientific also made an upfront payment of NIS 25 million ($6.8 million) to Allium. The agreement gives Boston Scientific a three-year license to distribute Alliums products and the option to acquire all of Gardia Medicals assets and rights. Alliums stock fell nearly 14% since the announcement.

Partners

Funding

Team Members

3

Employees: 1-10

Web & Social Links

Locations

Ha-Eshel Street 2, Caesarea, Israel

Photos & Videos

3 item(s)

ProCatid Medical Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info